Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
07:05am, Tuesday, 13'th May 2025
FDA assigns PDUFA target action date of November 9, 2025 RGX-121 on track to be the first gene therapy and one-time treatment for MPS II Partner Nippon Shinyaku to lead commercialization upon poten
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
06:30pm, Monday, 12'th May 2025
Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago.
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
04:05pm, Monday, 12'th May 2025
RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
07:05am, Thursday, 08'th May 2025
ROCKVILLE, Md. , May 8, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Tuesday, 06'th May 2025
ROCKVILLE, Md. , May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: BofA Securities Health Care Conference 2025 Presen
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:05am, Monday, 05'th May 2025
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
04:05pm, Wednesday, 30'th Apr 2025
ROCKVILLE, Md. , April 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, May 12, at 4:30 p.m.
5 Reasons To Buy Regenxbio Right Now
12:31pm, Wednesday, 26'th Mar 2025
Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, wit
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
09:15am, Wednesday, 19'th Mar 2025
Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% comp
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
06:44pm, Thursday, 13'th Mar 2025
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & Chief Executive Offic
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
06:25pm, Thursday, 13'th Mar 2025
Regenxbio (RGNX) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
04:05pm, Thursday, 13'th Mar 2025
Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potent
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
07:05am, Monday, 10'th Mar 2025
ROCKVILLE, Md. , March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the
Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know
11:05am, Thursday, 06'th Mar 2025
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
07:31am, Tuesday, 04'th Mar 2025
ROCKVILLE, Md. , March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku.
